158 related articles for article (PubMed ID: 18337642)
1. The similarities of aromatase inhibitors outweigh the differences.
Jänicke F
Anticancer Drugs; 2008 Mar; 19 Suppl 2():S7-9. PubMed ID: 18337642
[TBL] [Abstract][Full Text] [Related]
2. Current concepts in the endocrine therapy of breast cancer: tamoxifen and aromatase inhibitors.
Singh Ranger G
J Clin Pharm Ther; 2005 Aug; 30(4):313-7. PubMed ID: 15985044
[TBL] [Abstract][Full Text] [Related]
3. Early switch with aromatase inhibitors as adjuvant hormonal therapy for postmenopausal breast cancer: pooled-analysis of 8794 patients.
Bria E; Ciccarese M; Giannarelli D; Cuppone F; Nisticò C; Nuzzo C; Natoli G; Fabi A; Terzoli E; Cognetti F; Carlini P
Cancer Treat Rev; 2006 Aug; 32(5):325-32. PubMed ID: 16766125
[TBL] [Abstract][Full Text] [Related]
4. Clinical decision making in breast cancer: TAM and aromatase inhibitors for older patients -- a jungle?
Biganzoli L; Licitra S; Claudino W; Pestrin M; Leo AD
Eur J Cancer; 2007 Oct; 43(15):2270-8. PubMed ID: 17698345
[TBL] [Abstract][Full Text] [Related]
5. Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-receptor-positive early breast cancer.
Chlebowski RT
Breast Cancer Res Treat; 2008 Dec; 112 Suppl 1():25-34. PubMed ID: 19101792
[TBL] [Abstract][Full Text] [Related]
6. Advances in adjuvant hormonal therapy for postmenopausal women.
Strasser-Weippl K; Goss PE
J Clin Oncol; 2005 Mar; 23(8):1751-9. PubMed ID: 15755983
[No Abstract] [Full Text] [Related]
7. Reducing the risk of distant metastases: a better end point in adjuvant aromatase inhibitor breast cancer trials?
Tang SC
Cancer Invest; 2008 Jun; 26(5):481-90. PubMed ID: 18568770
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant endocrine therapy for perimenopausal women with early breast cancer.
Ortmann O; Cufer T; Dixon JM; Maass N; Marchetti P; Pagani O; Pronzato P; Semiglazov V; Spano JP; Vrdoljak E; Wildiers H
Breast; 2009 Feb; 18(1):2-7. PubMed ID: 19036588
[TBL] [Abstract][Full Text] [Related]
9. Addressing the future: combination with targeted therapies, adjuvant setting and beyond.
Goss PE
Anticancer Drugs; 2008 Mar; 19 Suppl 2():S3-5. PubMed ID: 18337641
[TBL] [Abstract][Full Text] [Related]
10. Aromatase inhibitors in adjuvant therapy of breast cancer: before, instead of, or beyond tamoxifen.
Pritchard KI
J Clin Oncol; 2005 Aug; 23(22):4850-2. PubMed ID: 16009956
[No Abstract] [Full Text] [Related]
11. The evolution of adjuvant endocrine therapy: developments since St Gallen 2005.
Smith IE; Arnedos M
Breast; 2007 Dec; 16 Suppl 2():S4-9. PubMed ID: 17764939
[TBL] [Abstract][Full Text] [Related]
12. A practical overview of aromatase inhibitors.
Younus J; Vandenberg TA
Anticancer Res; 2005; 25(3c):2497-502. PubMed ID: 16080483
[TBL] [Abstract][Full Text] [Related]
13. Translating trial data into patients benefits: making the right choice.
Chlebowski RT
Breast; 2008 Apr; 17 Suppl 3():S9-15. PubMed ID: 18367397
[TBL] [Abstract][Full Text] [Related]
14. Aromatase inhibitors as adjuvant therapy for breast cancer: overall survival versus disease-free survival as a primary end point in clinical practice.
Sánchez-Muñoz A; Ribelles N; Márquez A; Pérez-Ruiz E; Alba E
J Clin Oncol; 2009 Dec; 27(35):e255-6; author reply e257-8. PubMed ID: 19884520
[No Abstract] [Full Text] [Related]
15. Reducing the risk of distant metastases in breast cancer patients: role of aromatase inhibitors.
Del Mastro L; Clavarezza M; Venturini M
Cancer Treat Rev; 2007 Dec; 33(8):681-7. PubMed ID: 17850976
[TBL] [Abstract][Full Text] [Related]
16. Advances in adjuvant endocrine therapy for postmenopausal women.
Lin NU; Winer EP
J Clin Oncol; 2008 Feb; 26(5):798-805. PubMed ID: 18258989
[TBL] [Abstract][Full Text] [Related]
17. The optimal duration of adjuvant hormonal therapy for early-stage breast cancer.
Winer E
Clin Adv Hematol Oncol; 2008 Aug; 6(8):573-4. PubMed ID: 18820598
[No Abstract] [Full Text] [Related]
18. Prospects of neoadjuvant aromatase inhibitor therapy in breast cancer.
Dixon JM
Expert Rev Anticancer Ther; 2008 Mar; 8(3):453-63. PubMed ID: 18366292
[TBL] [Abstract][Full Text] [Related]
19. Risk reduction of distant metastasis in hormone-sensitive postmenopausal breast cancer.
Toi M; Yamashiro H; Tsuji W
Breast Cancer; 2009; 16(3):207-18. PubMed ID: 19259765
[TBL] [Abstract][Full Text] [Related]
20. Tamoxifen in breast cancer: not so easy to write off.
Munshi A; Singh P
Breast; 2008 Apr; 17(2):121-4. PubMed ID: 17923407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]